SEC Form 4 · accession 0001437749-18-017909
Oxford Immunotec Global PLC · OXFD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Peter Wrighton-Smith
Officer — Chief Executive Officer · Director
Period of report
Oct 1, 2018
Accepted (ET)
Oct 3, 2018 · 4:30 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001586049
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Oct 1, 2018 | S | 10,000 | $16.50 | D | 443,469 | D | |
| Ordinary SharesF2 | Oct 2, 2018 | S | 10,000 | $16.926 | D | 433,469 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 10, 2015, as amended.
- F2The price reported for the sales on October 2, 2018 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.90 to $16.9750 per share, inclusive. The reporting person undertakes to provide Oxford Immunotec Global PLC, or any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4.